Nilonix

Indication:

1. First line treatment in newly diagnosed Ph+ CML-CP

  • The effectiveness of Nilonix (Nilotinib) is based on major molecular response and cytogenetic response rates.
  • The recommended dose of Nilonix (Nilotinib) is 300 mg orally twice daily.

2. Resistant or Intolerant Ph+ CML-CP & CML-AP

  • The effectiveness of Nilonix (Nilotinib) is based on hematologic and cytogenetic response rates.
  • The recommended dose of Nilonix (Nilotinib) is 400 mg orally twice daily.

 

Strength & dosage form:

  • 150 mg Capsule